What is the 13F Pro Quality Score for CELU?

13F Pro ranks Celularity Inc (CELU) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CELU's current score at https://13fpro.ai/research/CELU (free sign-up required for the full ranking).

Where does 13F Pro source CELU data?

All Celularity Inc fundamentals and ownership data come directly from SEC EDGAR. Celularity Inc files with the SEC under CIK 1752828. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CELU in?

Celularity Inc (CELU) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CELU research updated on 13F Pro?

CELU's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Celularity Inc(CELU)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1752828 CELU stock profile & AI dashboard →

13F Pro Quality Score

22.4/100

Rank #2,638 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

73.9/100

Profitability

4.7/100

Balance Sheet

1.4/100

Earnings Quality

30.0/100

Free Cash Flow

12.4/100

Institutional Flow

33.1/100

Revenue Scale

7.8/100

Dilution Risk

5.3/100

CELU Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Celularity Inc (CELU), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CELU at 22.4/100 on a 32-signal composite quality model, placing it at rank #2,638 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.4) and profitability (4.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), Celularity Inc reports quarterly revenue of $4.1M, net income of $-24.4M, free cash flow of $-5.1M. Top institutional holders of CELU by reported 13-F value include C V STARR & CO, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. CELU trades on the Nasdaq exchange and files with the SEC under CIK 1752828. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CELU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Celularity Inc directly from SEC EDGAR. Celularity Inc's 13F Pro composite quality score has ranged between 7 and 51 since 2022, currently 22.4 — a declining long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about Celularity Inc

Quirks, history, and lore behind CELU — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · listed on Nasdaq · headquartered in New Jersey · focused on cell therapy and regenerative medicine.
2
The Numbers
A small-cap clinical-stage company with minimal revenue and a cash burn that keeps investors watching the balance sheet — the kind of stock that moves on trial data, not earnings.
3
The History
Spun out of Celgene around 2017, it inherited a platform built on the idea that the human placenta is an underutilized source of therapeutic cells.
4
The Secret
Its core technology involves harvesting postpartum placental tissue to manufacture allogeneic cell therapies — meaning one donor's cells can potentially treat many patients.
5
The Lore
The company's pipeline targets cancer, infectious disease, and aging, and its founder brought deep expertise from building the cord blood banking industry before pivoting to placenta-derived cells.
6
The Giveaway
Its very name is a mashup of "cellular" and a nod to its origins — a Celgene spinoff turning placental biology into off-the-shelf cell medicines, trading under a four-letter ticker starting with C-E-L.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q4 2025

$4.1M

Net Income

Q4 2025

$-24.4M

Free Cash Flow

Q4 2025

$-5.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-51.0% YoY

$26.6MFY 2025

FY22 $18.0MFY24 $54.2MFY25 $26.6M

Net Income

-58.4% YoY

$-91.7MFY 2025

FY22 $14.2MFY24 $-57.9MFY25 $-91.7M

Operating Income

-59.8% YoY

$-61.3MFY 2025

FY22 $-25.6MFY24 $-38.4MFY25 $-61.3M

EPS (Diluted)

-36.0% YoY

$-3.59FY 2025

FY22 $0.09FY24 $-2.64FY25 $-3.59

Total Assets

-19.1% YoY

$107.3MFY 2025

FY22 $401.1MFY24 $132.7MFY25 $107.3M

Total Debt

$33.8MFY 2025

FY22 $37.6MFY24 —FY25 $33.8M

Op. Cash Flow

-107.1% YoY

$-13.3MFY 2025

FY22 $-137.9MFY24 $-6.4MFY25 $-13.3M

Metric	FY 2025	FY 2024	FY 2022
Revenue	$26.6M -51.0%	$54.2M +201.6%	$18.0M
Net Income	$-91.7M -58.4%	$-57.9M -507.9%	$14.2M
Operating Income	$-61.3M -59.8%	$-38.4M -49.8%	$-25.6M
EPS (Diluted)	$-3.59 -36.0%	$-2.64 -3155.6%	$0.09
Total Assets	$107.3M -19.1%	$132.7M -66.9%	$401.1M
Total Debt	$33.8M	—	$37.6M
Operating Cash Flow	$-13.3M -107.1%	$-6.4M +95.4%	$-137.9M

AI Insight: CELU Financial Trends

Revenue collapsed from $18M in Q4 2024 to $4M in Q4 2025 while equity turned deeply negative at -$38M, signaling acute financial distress.

• Revenue fell sharply from $18M in Q4 2024 to $4M in Q4 2025, a decline of roughly 78% in four quarters.

• Operating losses deepened from -$9M in Q4 2024 to -$22M in Q4 2025, the worst level in the observed period.

• Equity deteriorated from $9M in Q4 2024 to -$38M in Q4 2025, reflecting cumulative net losses exceeding $47M in that span.

• Total debt rebounded to $34–$36M in Q3–Q4 2025 after briefly dropping to $6M in Q1–Q2 2025, raising leverage concerns.

⚠ Operating cash outflow worsened to -$5M in Q4 2025; with negative equity and rising debt, liquidity runway is a critical risk.

⚠ Revenue has now declined four consecutive quarters to $4M — watch whether any stabilization or new contracts emerge.

⚠ Debt jumped from $6M in Q2 2025 to $36M in Q3 2025; terms and covenants on this new borrowing warrant close scrutiny.

AI Insight: CELU Ratio Trends

Celularity's financials show near-universal data gaps and deeply negative returns, with ROA deteriorating to -90.8% in Q4 2025 — signaling severe ongoing capital destruction.

• ROA worsened steadily from -19.1% in Q2 2024 to -90.8% in Q4 2025, indicating accelerating asset-level losses.

• A Q3 2024 (Jul 29) anomaly shows OpMargin of 109.9% and ROE of 93.2% — likely a one-off gain distorting the trend.

• OpMargin, NPM, ROE, ROIC, and D/E data are entirely absent from Q2 2025 onward, severely limiting visibility.

⚠ ROA has been negative every quarter except the Jul-29 anomaly; the -90.8% reading in Q4 2025 is the worst on record.

⚠ D/E rose from 1.47 in Q2 2024 to 2.47 by Q3 2024 before going unreported — leverage trajectory warrants disclosure.

Get alerted when CELU's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Celularity Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CELU

C V STARR & CO INC
$1.0M764,069 sh
VANGUARD CAPITAL MANAGEMENT LLC
$826.1K621,105 sh
GEODE CAPITAL MANAGEMENT, LLC
$254.2K191,076 sh
BlackRock, Inc.
$169.6K127,501 sh
VANGUARD FIDUCIARY TRUST CO
$106.2K79,874 sh
STATE STREET CORP
$76.9K57,830 sh
Valmark Advisers, Inc.
$66.5K49,983 sh
NORTHERN TRUST CORP
$58.7K44,163 sh
HB Wealth Management, LLC
$53.8K40,415 sh
Biltmore Family Office, LLC
$46.5K35,000 sh

Fund	Value	Shares
C V STARR & CO INC	$1.0M	764,069
VANGUARD CAPITAL MANAGEMENT LLC	$826.1K	621,105
GEODE CAPITAL MANAGEMENT, LLC	$254.2K	191,076
BlackRock, Inc.	$169.6K	127,501
VANGUARD FIDUCIARY TRUST CO	$106.2K	79,874
STATE STREET CORP	$76.9K	57,830
Valmark Advisers, Inc.	$66.5K	49,983
NORTHERN TRUST CORP	$58.7K	44,163
HB Wealth Management, LLC	$53.8K	40,415
Biltmore Family Office, LLC	$46.5K	35,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CELU on your watchlist

Track score changes the day Celularity Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CELU a good stock to buy?

13F Pro's AI-powered analysis of Celularity Inc (CELU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CELU are available on the CELU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CELU?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CELU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Celularity Inc's investment landscape.